1. Acute lymphoblastic leukemia in a patient with chronic cyanoacrylate exposure.
- Author
-
Layden BT, Joseph M, Tallman MS, and Platanias LC
- Subjects
- Adhesives pharmacokinetics, Adult, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Asparaginase administration & dosage, Cyanoacrylates pharmacokinetics, Cyclophosphamide administration & dosage, Cytarabine administration & dosage, Daunorubicin administration & dosage, Dexamethasone administration & dosage, Doxorubicin administration & dosage, Humans, Male, Mercaptopurine administration & dosage, Methotrexate administration & dosage, Mouth Mucosa metabolism, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma drug therapy, Prednisone administration & dosage, Recurrence, Remission Induction, Salvage Therapy, Vincristine administration & dosage, Adhesives adverse effects, Cyanoacrylates adverse effects, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma chemically induced, Self Care adverse effects, Tooth Fractures therapy
- Abstract
Environmental agents have long been thought to be linked to the development of malignancies. Due to the difficulty in identifying and verifying exposures to such agents, only a few chemical compounds are clearly linked to malignancies. We report here the case of a 36-year-old man with pre-B cell acute lymphoblastic leukemia. This patient was using industrial strength glue to reattach a chipped tooth for approximately 1 year, and such use was associated with chronic exposure of his oral mucosa to this glue. This case raises the possibility that chronic exposure to cyanoacrylates, the adhesive agents in industrial strength glue, may be associated with the development of acute lymphoblastic leukemia in humans., (Copyright 2007 S. Karger AG, Basel.)
- Published
- 2007
- Full Text
- View/download PDF